Results 31 to 40 of about 569,111 (191)

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Blood, 2019
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.
C. Dinardo, K. Pratz, V. Pullarkat, B. Jonas, M. Arellano, P. Becker, O. Frankfurt, M. Konopleva, A. Wei, H. Kantarjian, T. Xu, W. Hong, B. Chyla, J. Potluri, D. Pollyea, A. Letai   +15 more
semanticscholar   +1 more source

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

Cancer, 2021
Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML).
K. Sasaki, F. Ravandi, T. Kadia, C. Dinardo, N. Short, G. Borthakur, E. Jabbour, H. Kantarjian   +7 more
semanticscholar   +1 more source

FLT3 mutations in Early T-Cell Precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors [PDF]

, 2013
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T-lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults.
Baldus, Claudia D., Bartram, Isabelle, Blau, Olga, Brandts, Christian Hubertus, Burmeister, Thomas, Coskun, Ebru, Döhner, Hartmut, Dührsen, Ulrich, Ehninger, Gerhard, Fransecky, Lars, Griesshammer, Martin, Gökbuget, Nicola, Haas, Rainer, Heesch, Sandra, Hoelzer, Dieter, Hofmann, Wolf-Karsten, Mochmann, Liliana H., Neumann, Martin, Sartangi, Nasrin Farhadi, Schlee, Cornelia, Schwartz, Stefan, Thiel, Eckhard   +21 more
core   +7 more sources

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

Radiation-induced myeloid leukemia in murine models. [PDF]

, 2014
The use of radiation therapy is a cornerstone of modern cancer treatment. The number of patients that undergo radiation as a part of their therapy regimen is only increasing every year, but this does not come without cost.
Davoren, Michael, Rivina, Leena, Schiestl, Robert H   +2 more
core   +2 more sources

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Blood, 2017
Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked
E. Stein, C. Dinardo, D. Pollyea, A. Fathi, G. Roboz, J. Altman, R. Stone, D. DeAngelo, R. Levine, I. Flinn, H. Kantarjian, R. Collins, M. Patel, A. Frankel, A. Stein, M. Sekeres, R. Swords, B. Medeiros, C. Willekens, P. Vyas, A. Tosolini, Qiang Xu, R. Knight, K. Yen, S. Agresta, S. de Botton, M. Tallman   +26 more
semanticscholar   +1 more source

Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion [PDF]

, 2015
Herein, we describe the establishment and characterization of the first mixed-phenotype acute leukemia cell line (JIH-5). The JIH-5 cell line was established from leukemia cells with B lymphoid/myeloid phenotype from a female mixed-phenotype acute ...
Changgeng Ruan, Haiping Dai, Hans G. Drexler, Huiying Qiu, Nana Ping, Qian Wang, Roderick A. F. MacLeod, Stefan Ehrentraut, Suning Chen   +8 more
core   +1 more source

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

New England Journal of Medicine, 2012
BACKGROUND Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for ...
Jay P. Patel, M. Gönen, M. Figueroa, H. Fernandez, Zhuoxin Sun, J. Racevskis, P. Van Vlierberghe, Igor Dolgalev, S. Thomas, Olga S. Aminova, K. Huberman, Janice Cheng, A. Viale, N. Socci, A. Heguy, A. Cherry, G. Vance, R. Higgins, R. Ketterling, R. Gallagher, M. Litzow, M. V. D. van den Brink, H. Lazarus, J. Rowe, S. Luger, A. Ferrando, E. Paietta, M. Tallman, A. Melnick, O. Abdel-Wahab, R. Levine   +30 more
semanticscholar   +1 more source

Functional Genomic Landscape of Acute Myeloid Leukemia

Nature, 2018
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events.
J. Tyner, C. Tognon, D. Bottomly, Beth Wilmot, S. Kurtz, S. Savage, Nicola Long, Anna Reister Schultz, E. Traer, Melissa L. Abel, A. Agarwal, A. Blucher, U. Borate, Jade Bryant, Russell T. Burke, A. Carlos, Richie Carpenter, J. Carroll, B. Chang, Cody Coblentz, Amanda d’Almeida, R. Cook, A. Danilov, K. Dao, Michie Degnin, D. Devine, J. Dibb, David K Edwards, C. Eide, I. English, J. Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, A. Kaempf, Jessica T. Leonard, Chen-Jzong Lin, S. Liu, Pierrette Lo, M. Loriaux, Samuel B. Luty, T. Macey, Jason D. MacManiman, Jacqueline Martinez, M. Mori, D. Nelson, Ceilidh Nichols, Jill Peters, Justin W Ramsdill, Angela Rofelty, R. Schuff, R. Searles, E. Segerdell, Rebecca Smith, S. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jacob P. Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, C. Cogle, R. Collins, D. Connolly, M. Deininger, L. Drusbosky, C. Hourigan, C. Jordan, P. Kropf, Tara L. Lin, Micaela E. Martinez, B. Medeiros, Rachel R. Pallapati, D. Pollyea, R. Swords, J. Watts, S. Weir, D. Wiest, R. M. Winters, S. McWeeney, B. Druker   +87 more
semanticscholar   +1 more source

Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML [PDF]

, 2002
HTIF1α, a transcription coactivator which is able to mediate RARα activity and functionally interact with PML, is encoded by a gene on chromosome 7q32–34, which is a critical region in acute myeloid leukemias (AML). With the assumption that this gene may
AGUIARI, Gianluca, CASTOLDI, GL, CUNEO, Antonio, DE ANGELI, C, DEL SENNO, Laura, GANDINI, D, LANZA, F, MANZATI, E, PANDOLFI, PP   +8 more
core   +1 more source